Please wait...
Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:
USARx offers multiple ways to purchase this medication. Choose the Best option for you!
Acid- or proton-pump inhibitor; gastric antisecretory agent.
Short-term treatment of symptomatic GERD (e.g., heartburn) in patients without erosive esophagitis.
Short-term treatment of erosive esophagitis in patients with GERD.
Maintain healing and decrease recurrence of erosive esophagitis.
Short-term treatment of active duodenal ulcer.
Treatment of Helicobacter pylori infection and duodenal ulcer disease. Used in conjunction with amoxicillin and clarithromycin (triple therapy).
Long-term treatment of pathologic GI hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
Some evidence for use of proton-pump inhibitors (e.g., omeprazole) for gastric acid suppressive therapy as an adjunct in the management of upper GI Crohn’s disease†, including esophageal†, gastroduodenal†, and jejunoileal† disease.
Administer orally; may give without regard to meals, but manufacturer recommends administration after morning meal in patients with duodenal ulcer.
When used in combination with clarithromycin and amoxicillin for treatment of H. pylori infection and duodenal ulcer disease, take all 3 drugs twice daily with morning and evening meals.
Swallow tablets intact; do not chew, crush, or split.
Antacids may be used concomitantly as needed for pain relief.
Available as rabeprazole sodium; dosage expressed in terms of the salt.
Adolescents ≥12 years of age: 20 mg once daily for up to 8 weeks.
20 mg once daily for 4 weeks; may give additional 4 weeks if symptoms are not completely resolved.
20 mg once daily for 4–8 weeks. If not healed after 8 weeks, consider additional 8 weeks of therapy (up to 16 weeks for a single course).
20 mg once daily. Chronic, lifelong therapy may be appropriate.
20 mg once daily for up to 4 weeks; some patients may require additional therapy.
Triple therapy: 20 mg twice daily for 7 days in conjunction with amoxicillin and clarithromycin.
60 mg once daily. Dosages up to 100 mg once daily or 60 mg twice daily have been used. Divided doses may be required. Adjust dosage as needed, continue treatment as long as necessary. Has been used continuously for up to 1 year.
Known hypersensitivity to rabeprazole, any ingredient in the formulation, or other substituted benzimidazoles (e.g., esomeprazole, lansoprazole, pantoprazole, omeprazole).
Response to rabeprazole does not preclude presence of occult gastric neoplasm.
Proton-pump inhibitors associated with possible increased (1.4–2.75 times) risk of Clostridium difficile infection, including C. difficile-associated diarrhea and colitis (CDAD; also known as antibiotic-associated diarrhea and colitis or pseudomembranous colitis). Many patients also had other risk factors for CDAD. May be severe; colectomy and, rarely, death reported.
Use the lowest effective dosage and shortest duration of therapy appropriate for the patient's clinical condition.
Consider CDAD if persistent diarrhea develops and manage accordingly; initiate supportive therapy (e.g., fluid and electrolyte management), anti-infective therapy directed against C. difficile (e.g., metronidazole, vancomycin), and surgical evaluation as clinically indicated.
Administration of proton-pump inhibitors has been associated with an increased risk for developing certain infections (e.g., community-acquired pneumonia).
Several observational studies suggest that use of proton-pump inhibitors, particularly in high dosages (i.e., multiple daily doses) and/or for prolonged periods of time (i.e., ≥1 year), may be associated with increased risk of osteoporosis-related fractures of the hip, wrist, or spine. Magnitude of risk is unclear; causality not established. FDA is continuing to evaluate this safety concern.
Use the lowest effective dosage and shortest duration of therapy appropriate for the patient’s clinical condition.
Individuals at risk for osteoporosis-related fractures should receive an adequate intake of calcium and vitamin D; assess and manage these patients’ bone health according to current standards of care.
Hypomagnesemia, symptomatic and asymptomatic, reported rarely in patients receiving long-term therapy (≥3 months or, in most cases, >1 year) with proton-pump inhibitors, including rabeprazole. Serious adverse effects include tetany, seizures, tremors, carpopedal spasm, arrhythmias (e.g., atrial fibrillation, supraventricular tachycardia), and abnormal QT interval. Paresthesia, muscle weakness, muscle cramps, lethargy, fatigue, and unsteadiness may occur. Most patients required magnesium replacement and discontinuance of the proton-pump inhibitor. Hypomagnesemia resolved within 1 week (median) following discontinuance and recurred within 2 weeks (median) of rechallenge.
In patients expected to receive long-term proton-pump inhibitor therapy or in patients currently receiving digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), consider measuring serum magnesium concentrations prior to initiation of prescription proton-pump inhibitor therapy and periodically thereafter.
Category B.
Not known whether rabeprazole is distributed into milk; discontinue nursing or the drug.
Safety and efficacy for short-term treatment of symptomatic GERD established in adolescents 12–16 years of age. Pharmacokinetic and adverse effect profiles similar to those in adults.
Safety and efficacy not established in children <12 years of age.
No substantial differences in safety or efficacy relative to younger adults, but increased sensitivity cannot be ruled out.
Use with caution in patients with severe impairment.
Pain, pharyngitis, flatulence, infection, constipation.
Metabolized in the liver, principally by CYP3A and 2C19 isoenzymes.
No clinically important interactions with some drugs that are metabolized by CYP isoenzymes under single dose conditions; effects of rabeprazole have not been studied under steady-state conditions.
Potential pharmacologic interaction (possible increased risk of hypomagnesemia). Consider monitoring magnesium concentrations prior to initiation of prescription proton-pump inhibitor therapy and periodically thereafter. (See Hypomagnesemia under Cautions.)
Drug
Interaction
Comments
Amoxicillin
Increased rabeprazole and 14-hydroxyclarithromycin AUC and plasma concentrations when administered with amoxicillin and clarithromycin
Not expected to result in toxicity
Antacids
No clinically important effects on rabeprazole pharmacokinetics
Atazanavir
Possible altered oral absorption of atazanavir, resulting in decreased plasma atazanavir concentrations; possible loss of virologic response
Manufacturer of rabeprazole states that concomitant administration with atazanavir is not recommended
Antiretroviral treatment-naive patients: If a proton-pump inhibitor is used concomitantly with atazanavir, administer ritonavir-boosted atazanavir (atazanavir 300 mg and ritonavir 100 mg once daily with food); administer the proton-pump inhibitor approximately 12 hours before ritonavir-boosted atazanavir
For treatment-naive patients, dosage of proton-pump inhibitor should not exceed omeprazole 20 mg daily (or equivalent)
Antiretroviral treatment-experienced patients: Concomitant use of proton-pump inhibitors with atazanavir not recommended
Clarithromycin
Increased rabeprazole and 14-hydroxyclarithromycin AUC and plasma concentrations when administered with amoxicillin and clarithromycin
Not expected to result in toxicity
Clopidogrel
Certain CYP2C19 inhibitors (e.g., omeprazole, esomeprazole) reduce exposure to clopidogrel’s active metabolite and decrease platelet inhibitory effect; potentially may reduce clopidogrel’s clinical efficacy
Dexlansoprazole, lansoprazole, or pantoprazole had less effect on clopidogrel's antiplatelet activity than did omeprazole or esomeprazole
Assess risks and benefits of concomitant proton-pump inhibitor and clopidogrel use in individual patients
American College of Cardiology Foundation/American College of Gastroenterology/American Heart Association (ACCF/ACG/AHA) states that GI bleeding risk reduction with concomitant proton-pump inhibitor in patients with risk factors for GI bleeding (e.g., advanced age; concomitant use of warfarin, corticosteroids, or NSAIAs; H. pylori infection) may outweigh potential reduction in cardiovascular efficacy of antiplatelet treatment associated with a drug-drug interaction. In patients without such risk factors, ACCF/ACG/AHA states that risk/benefit balance may favor use of antiplatelet therapy without a proton-pump inhibitor.
If concomitant therapy with a proton-pump inhibitor and clopidogrel is deemed necessary, consider using an agent with little or no CYP2C19-inhibitory activity; alternatively, consider using a histamine H2-receptor antagonist (ranitidine, famotidine, nizatidine) but not cimetidine (also a potent CYP2C19 inhibitor)
Cyclosporine
Rabeprazole inhibited cyclosporine metabolism in vitro
Diazepam
No pharmacokinetic interaction observed after single doses
Digoxin
Hypomagnesemia (e.g., resulting from long-term use of proton-pump inhibitors) sensitizes the myocardium to digoxin and, thus, may increase risk of digoxin-induced cardiotoxic effects
See table entry for gastric pH-dependent drugs
Consider monitoring magnesium concentrations prior to initiation of prescription proton-pump inhibitor therapy and periodically thereafter
Diuretics (i.e., loop or thiazide diuretics)
Possible increased risk of hypomagnesemia
Consider monitoring magnesium concentrations prior to initiation of prescription proton-pump inhibitor therapy and periodically thereafter
Fosamprenavir
Use of esomeprazole with fosamprenavir (with or without ritonavir) did not substantially affect concentrations of amprenavir (active metabolite of fosamprenavir)
No dosage adjustment required when proton-pump inhibitors used with fosamprenavir (with or without ritonavir)
Gastric pH-dependent drugs (e.g., digoxin, ketoconazole)
Rabeprazole may alter drug absorption
Monitor if used concomitantly
Lopinavir
Lopinavir/ritonavir: Omeprazole had no clinically important effect on plasma concentrations or AUC of lopinavir
No dosage adjustment required when proton-pump inhibitors used with lopinavir/ritonavir
Methotrexate (high-dose)
Possible delayed clearance and increased serum concentrations of methotrexate and/or its metabolite hydroxymethotrexate; possible methotrexate toxicity
Reported mainly with high-dose methotrexate (300 mg/m2 to 12 g/m2), but also reported with low dosages (e.g., 15 mg per week)
Manufacturer of rabeprazole recommends considering temporary discontinuance of proton-pump inhibitor therapy in some patients receiving high-dose methotrexate
Some clinicians recommend withholding the proton-pump inhibitor for several days before and after administration of either high-dose or low-dose methotrexate or, alternatively, substituting a histamine H2-receptor antagonist for the proton-pump inhibitor
Phenytoin
No pharmacokinetic interaction observed after single doses
Raltegravir
Omeprazole increased peak plasma concentration and AUC of raltegravir
No dosage adjustment recommended when proton-pump inhibitors used with raltegravir
Rilpivirine
Omeprazole decreased plasma concentrations and AUC of rilpivirine
Concomitant use of rilpivirine and proton-pump inhibitors contraindicated
Saquinavir
Ritonavir-boosted saquinavir: Omeprazole increased peak plasma concentration and AUC of saquinavir
Caution advised if proton-pump inhibitor used with ritonavir-boosted saquinavir; monitor for saquinavir toxicity
Sucralfate
Possible delayed proton-pump inhibitor absorption and decreased bioavailability
Administer proton-pump inhibitor at least 30 minutes before sucralfate
Theophylline
No pharmacokinetic interaction observed after single doses
Warfarin
Potential for increased INR and PT
Monitor PT and INR
Absolute bioavailability with 20 mg dose is about 52%. Repeated dosing does not affect pharmacokinetics.
Within 1 hour. Median inhibition of 24-hour gastric acidity is 88% of maximum after first dose.
High-fat meal may delay absorption but does not affect extent.
AUC increased 50–60% in Japanese males receiving a different rabeprazole formulation.
AUC doubled in patients with mild to moderate compensated cirrhosis. Peak plasma concentrations and AUCs increased 20% in patients with mild to moderate hepatic impairment.
In geriatric patients, peak plasma concentration increased by 60% and AUCs doubled.
Not known whether rabeprazole crosses the placenta or is distributed into milk.
Prolonged binding to gastric parietal proton pump enzyme.
Approximately 96%.
Metabolized in the liver, principally by CYP3A and CYP2C19. Principal thioether and sulphone metabolites found in plasma are inactive.
Excreted as metabolites in urine (90%); remainder in feces.
1–2 hours.
In patients with mild to moderate compensated cirrhosis, elimination half-life was 2–3 times greater, and clearance decreased to less than one-half.
In patients with poor CYP2C19 metabolizer phenotype, metabolism is slower than in those with extensive (or rapid) metabolizer phenotype.
25°C (may be exposed to 15–30°C). Protect from moisture.
Inhibits basal and stimulated gastric acid secretion.
Concentrates in acid conditions of parietal cell secretory canaliculi; forms active sulfenamide metabolite that binds to and inactivates hydrogen-potassium ATPase (proton- or acid-pump), blocking final step in secretion of hydrochloric acid. Sustained inactivation of hydrogen-potassium ATPase results in prolonged duration of action.
Suppresses gastric H. pylori in patients with duodenal ulcer and/or reflux esophagitis infected with the organism. Combined therapy with rabeprazole and one or more appropriate anti-infectives (e.g., amoxicillin, clarithromycin) can effectively eradicate H. pylori gastric infection.
Importance of swallowing tablets whole, without crushing or chewing.
Importance of advising patients that use of multiple daily doses of the drug for an extended period of time may increase the risk of fractures of the hip, wrist, or spine.
Risk of hypomagnesemia; importance of immediately reporting and seeking care for any cardiovascular or neurologic manifestations (e.g., palpitations, dizziness, seizures, tetany).
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs. Antacids may be used concomitantly as needed for pain relief.
Possible increased risk of Clostridium difficile infection; importance of contacting clinician if persistent watery stools, abdominal pain, and fever occur.
Importance of women informing their clinicians if they are or plan to become pregnant or plan to breast-feed.
Importance of informing patients of other important precautionary information. (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
Routes
Dosage Forms
Strengths
Brand Names
Manufacturer
Oral
Tablets, delayed-release (enteric-coated)
20 mg
AcipHex
Eisai (also promoted by Janssen [formerly Ortho-McNeil-Janssen])
AHFS DI Essentials™. © Copyright 2020, Selected Revisions February 15, 2013. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
† Use is not currently included in the labeling approved by the US Food and Drug Administration.
1. Eisai Inc. and Janssen Pharmaceuticals Inc. AcipHex (rabeprazole sodium) delayed-release tablets prescribing information. Woodcliff Lake and Titusville, NJ; 2012 May
2. Prakash A, Faulds D. Rabeprazole. Drugs. 1998; 55:261-7. http://www.ncbi.nlm.nih.gov/pubmed/9506245?dopt=AbstractPlus
3. Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs. 1998; 56:307-35. http://www.ncbi.nlm.nih.gov/pubmed/9777309?dopt=AbstractPlus
4. Morii M, Hamatani K, Takeguchi N. The proton pump inhibitor, E3810, binds to the N-terminal half of the α-subunit og gastric H+,K(+)-ATPase. Biochem Pharmacol. 1995; 16:1729-34.
5. Williams MP, Sercombe J, Hamilton MI et al. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther. 1998; 12:1079-89. http://www.ncbi.nlm.nih.gov/pubmed/9845397?dopt=AbstractPlus
6. Lew EA, Barbuti RC, Kovacs TO et al. An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810). Aliment Pharmacol Ther. 1998; 12:667-72. http://www.ncbi.nlm.nih.gov/pubmed/9701531?dopt=AbstractPlus
7. VandenBranden M, Ring BJ, Binkley SN et al. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics. 1996; 6:81-91. http://www.ncbi.nlm.nih.gov/pubmed/8845864?dopt=AbstractPlus
8. Yasuda S, Horai Y, Tomono Y et al. Comparison of the kinetic disposition and metabolism of E3810, a new proton inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin Pharmacol Ther. 1995; 58:143-54. http://www.ncbi.nlm.nih.gov/pubmed/7648764?dopt=AbstractPlus
9. Ishizaki T, Chiba K, Manabe K et al. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation. Clin Pharmacol Ther. 1995; 58:155-64. http://www.ncbi.nlm.nih.gov/pubmed/7648765?dopt=AbstractPlus
10. Miwa H, Ohkura R, Murai T et al. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther. 1999; 13:741-6. http://www.ncbi.nlm.nih.gov/pubmed/10383502?dopt=AbstractPlus
11. Stack WA, Knifton A, Thirwell D et al. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. Am J Gastroenterol. 1998; 93:1909-13. http://www.ncbi.nlm.nih.gov/pubmed/9772054?dopt=AbstractPlus
12. Tsuchiya M, Imamura L, Park JB et al. Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol Pharm Bull. 1995; 18:1053-6. http://www.ncbi.nlm.nih.gov/pubmed/8535394?dopt=AbstractPlus
13. Park JB, Imamura L, Kobashi K. Kinetic studies of Helicobacter pylori urease inhibition by a novel proton pump inhibitor, rabeprazole. Biol Pharm Bull. 1996; 19:182-7. http://www.ncbi.nlm.nih.gov/pubmed/8850302?dopt=AbstractPlus
14. Hirai M, Azuma T, Ito S et al. A proton pump inhibitor, E3810, has antibacterial activity through niding to Helicobacter pylori. J Gastroenterol. 1995; 30:461-4. http://www.ncbi.nlm.nih.gov/pubmed/7550855?dopt=AbstractPlus
15. Dekkers CP, Beker JA, Thjodleifsson B et al for the European Rabeprazole Study Group. Double-blind comparison (correction of double-blind, placebo-controlled comparison) of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1999; 13:49-57. http://www.ncbi.nlm.nih.gov/pubmed/9892879?dopt=AbstractPlus
16. National Institutes of Health Consensus Development Group. Gastroesophageal reflux disease (hiatal hernia and heartburn). NIH Publication No. 94-882; 1994 Sep.
17. Dekkers CP, Beker JA, Thjodleifsson B et al. Comparison of rabeprazole 20 mg versus omperazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. Aliment Pharmacol Ther. 1999; 13:179-86. http://www.ncbi.nlm.nih.gov/pubmed/10102948?dopt=AbstractPlus
18. Cloud ML, Enas N, Humphries TJ et al for the Rabeprazole Study Group. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). Dig Dis Sci. 1998; 43:993-1000. http://www.ncbi.nlm.nih.gov/pubmed/9590413?dopt=AbstractPlus
19. Yasuda S, Higashi S, Murakami M et al. Antacids have no influence on the pharmacokinetics of rabeprazole, a new proton pump inhibitor, in healthy volunteers. Int J Clin Pharmacol Ther. 1999; 37:249-53. http://www.ncbi.nlm.nih.gov/pubmed/10363624?dopt=AbstractPlus
20. Yasuda S, Ohnishi A, Ogawa T et al. Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther. 1994; 32:466-73. http://www.ncbi.nlm.nih.gov/pubmed/7820329?dopt=AbstractPlus
21. Hoyumpa AM, Trevino-Alanis H, Grimes I et al. Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis. Clin Ther. 1999; 21:691-701. http://www.ncbi.nlm.nih.gov/pubmed/10363734?dopt=AbstractPlus
22. Keane WF, Swan SK, Grimes I et al. Rabeprazole: pharmacokinetics and tolerability in patients with stable, end-stage renal failure. J Clin Pharmacol. 1999; 39:927-33. http://www.ncbi.nlm.nih.gov/pubmed/10471983?dopt=AbstractPlus
23. Eisai Inc. Teaneck, NJ: Personal communication.
24. Shinomura Y, Kanayama S, Miyazaki Y et al. A clinical study of the effects of E3810 (rabeprazole sodium) for the treatment of gastric and duodenal ulcers: a comparison of post-breakfast and bedtime dosing regimens. Mod Physician. 1994; 14:69-84.
25. Eisai Ltd. and Janssen-Cilag Pharmaceutica Inc. Pariet (rabeprazole sodium) gastro-resistant tablets product monograph. London, 1998 Sep. RabeprazoleRestricted Distribution/6
26. DeVault KR, Castell DO, Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 1999; 94:1434-42. http://www.ncbi.nlm.nih.gov/pubmed/10364004?dopt=AbstractPlus
27. Hanauer SB, Sandborn W, and the Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn’s disease in adults: Practice Guidelines. Am J Gastroenterol. 2001; 96:635-43. http://www.ncbi.nlm.nih.gov/pubmed/11280528?dopt=AbstractPlus
28. Valori RM, Cockel R. Omeprazole for duodenal ulceration in Crohn’s disease. Br Med J. 1990; 300:438-9.
29. Bianchi G, Ardizzone S, Petrillo M et al. Omeprazole for peptic ulcer in Crohn’s disease. Am J Gastroenterol. 1991; 86: 245-6. http://www.ncbi.nlm.nih.gov/pubmed/1992643?dopt=AbstractPlus
30. Przemioslo RT, Mee AS. Omeprazole in possible esophageal Crohn’s disease. Dig Dis Sci. 1994; 39:1594-5. http://www.ncbi.nlm.nih.gov/pubmed/8026276?dopt=AbstractPlus
31. Dickinson JB. Is omeprazole helpful in inflammatory bowel disease? J Clin Gastroenterol. 1994; 18:317-9.
32. Abrahao LJ Jr., Abrahao LJ, Vargas C et al. [Gastoduodenal Crohn’s disease—report of 4 cases and review of the literature]. (Portuguese; with English abstract.) Arq Gastroenterol. 2001; 38:57-62.
33. Freston JW. Review article: role of proton pump inhibitors in non-H. pylori-related ulcers. Aliment Pharmacol Ther. 20001; 15(Suppl 2):2-5.
34. TAP. Prevacid (lansoprazole) delayed-release capsules, for delayed-release oral suspension and delayed-release orally disintegrating tablets prescribing information. Lake Forest, IL; 2003 Aug.
35. Laheij RJF, Sturkenboom MCJM, Hassing RJ et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004; 292:1955-60. http://www.ncbi.nlm.nih.gov/pubmed/15507580?dopt=AbstractPlus
36. Gregor JC. Acid suppression and pneumonia.; a clinical indication for rational prescibing. JAMA. 2004;292:2012-3. Editorial.
37. AstraZeneca, Nexium (esomeprazole magnesium) delayed-release capsules prescribing information. Wilmington, DE; 2001 Aug.
38. TAP. Prevacid (lansoprazole) delayed-release capsules, for delayed-release oral suspension and delayed-release orally disintegrating tablets prescribing information. Lake Forest, IL; 2003 Aug.
39. Yang Y-X, Lewis JD, Epstein S et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006; 296:2947-53. http://www.ncbi.nlm.nih.gov/pubmed/17190895?dopt=AbstractPlus
41. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (Mar 29, 2012). From the US Department of Health and Human Services HIV/AIDS Information Services (AIDSinfo) website. http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/glchunk/glchunk_32.pdf
42. Bristol-Myers Squibb. Reyataz (atazanavir sulfate) capsules prescribing information. Princeton, NJ; 2012 Mar.
43. Gilard M, Arnaud B, Cornily JC et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. JACC. 2008; 51:256-60, doi:10.1016/j.jacc.2007.06.064. Accessed 2008 Dec 8. Available from website. http://www.ncbi.nlm.nih.gov/pubmed/18206732?dopt=AbstractPlus http://content.onlinejacc.org/cgi/content/abstract/51/3/256
44. Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. JACC. 2008; 52:1038-9. Letter. http://www.ncbi.nlm.nih.gov/pubmed/18786491?dopt=AbstractPlus
45. MEDCO. New study: A common class of GI medications reduce protection against heart attack in patients taking widely prescribed cardiovascular drug. Franklin Lakes, NJ; 2008 Nov 11. Press release from website. http://www.medco.com
46. Gilard M, Cornily JC, Boschat J. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. JACC. 2008; 52:1039. Reply.
47. . PPI interactions with clopidogrel revisited. Med Lett Drugs Ther. 2009; 51:13-4.
48. Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009; 180:713-8. http://www.ncbi.nlm.nih.gov/pubmed/19176635?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2659819&blobtype=pdf
49. Food and Drug Administration. Information on clopidogrel bisulfate (marketed as Plavix). Rockville, MD; 2010 Oct 27. From FDA website. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm190836.htm
219. Gilard M, Arnaud B, Cornily JC et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. JACC. 2008; 51:256-60, doi:10.1016/j.jacc.2007.06.064. Accessed 2008 Dec 8. Available from website. http://www.ncbi.nlm.nih.gov/pubmed/18206732?dopt=AbstractPlus http://content.onlinejacc.org/cgi/content/abstract/51/3/256
220. Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. JACC. 2008; 52:1038-9. Letter. http://www.ncbi.nlm.nih.gov/pubmed/18786491?dopt=AbstractPlus
221. MEDCO. New study: A common class of GI medications reduce protection against heart attack in patients taking widely prescribed cardiovascular drug. Franklin Lakes, NJ; 2008 Nov 11. Press release from website. http://www.medco.com
223. . PPI interactions with clopidogrel revisited. Med Lett Drugs Ther. 2009; 51:13-4.
224. Sanofi-Aventis/Bristol-Myers Squibb. Plavix, (clopidogrel bisulfate) tablets prescribing information. New York, NY; 2011 Dec.
225. Food and Drug Administration. Early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix). Rockville, MD; 2009 Jan 26. From FDA website. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm079520.htm
226. Siller-Matula JM, Spiel AO, Lang IM et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2009; 157:148.e1-5.
227. Gilard M, Arnaud B, Le Gal G et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 2006; 4:2508-9. http://www.ncbi.nlm.nih.gov/pubmed/16898956?dopt=AbstractPlus
228. Anon. PPI interactions with clopidogrel. Med Lett Drugs Ther. 2009; 51:2-3.
229. Aubert RE, Epstein RS, Teagarden JR et al. Proton pump inhibitors effect on clopidogrel effectiveness: The clopidogrel Medco outcomes study. Circulation. 2008; 118:S_815, Abstract 3998.
230. Lau WC, Gurbel PA. The drug-drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009; 180:699-700. http://www.ncbi.nlm.nih.gov/pubmed/19332744?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2659824&blobtype=pdf
232. Food and Drug Administration. Information for heathcare professionals: Update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert heathcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). Rockville, MD; 2009 Nov 17. From FDA website. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm190787.htm
233. Food and Drug Administration. Follow-up to the January 26, 2009 Early Communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix) and omeprazole (marketed as Prilosec and Prilosec OTC). Rockville, MD; 2009 Nov 17. From FDA website. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm190784.htm
234. Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009; 180:713-8. http://www.ncbi.nlm.nih.gov/pubmed/19176635?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2659819&blobtype=pdf
235. Ho PM, Maddox TM, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009; 301:937-44. http://www.ncbi.nlm.nih.gov/pubmed/19258584?dopt=AbstractPlus
236. Norgard NB, Mathews KD, Wall GC. Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother. 2009; 43:1266-74. http://www.ncbi.nlm.nih.gov/pubmed/19470853?dopt=AbstractPlus
237. Last EJ, Sheehan AH. Review of recent evidence: potential interaction between clopidogrel and proton pump inhibitors. Am J Health Syst Pharm. 2009; 66:2117-22. http://www.ncbi.nlm.nih.gov/pubmed/19923312?dopt=AbstractPlus
238. Stanek EJ, Aubert RE, Flockhart DA et al. A national study of the effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting: the Clopidogrel Medco Outcomes Study. Available at: http://www.theheart.org/displayItem.do?primaryKey=967345&type=ppt. Accessed 2009 Dec 15.
240. Stockl KM, Le L, Zakharyan A et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med. 2010; 170:704-10. http://www.ncbi.nlm.nih.gov/pubmed/20421557?dopt=AbstractPlus
243. Juurlink DN. Proton pump inhibitors and clopidogrel: putting the interaction in perspective. Circulation. 2009; 120:2310-2. http://www.ncbi.nlm.nih.gov/pubmed/19933929?dopt=AbstractPlus
248. Khalique SC, Cheng-Lai A. Drug interaction between clopidogrel and proton pump inhibitors. Cardiol Rev. 2009 Jul-Aug; 17:198-200.
250. Rude MK, Chey WD. Proton-pump inhibitors, clopidogrel, and cardiovascular adverse events: fact, fiction, or something in between?. Gastroenterology. 2009; 137:1168-71. http://www.ncbi.nlm.nih.gov/pubmed/19635603?dopt=AbstractPlus
300. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006; 79:76-83. http://www.ncbi.nlm.nih.gov/pubmed/16927047?dopt=AbstractPlus
301. Corley DA, Kubo A, Zhao W et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010; 139:93-101. http://www.ncbi.nlm.nih.gov/pubmed/20353792?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2902649&blobtype=pdf
302. Yu EW, Blackwell T, Ensrud KE et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008; 83:251-9. http://www.ncbi.nlm.nih.gov/pubmed/18813868?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2596870&blobtype=pdf
303. Gray SL, LaCroix AZ, Larson J et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med. 2010; 170:765-71. http://www.ncbi.nlm.nih.gov/pubmed/20458083?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4240017&blobtype=pdf
304. Targownik LE, Lix LM, Metge CJ et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008; 179:319-26. http://www.ncbi.nlm.nih.gov/pubmed/18695179?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2492962&blobtype=pdf
305. Food and Drug Administration. Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. May 25, 2010. From FDA web site (http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213206.htm).
307. Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology. 2010; :.
308. Targownik LE, Lix LM, Leung S et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010; 138:896-904. http://www.ncbi.nlm.nih.gov/pubmed/19931262?dopt=AbstractPlus
310. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008; 28:951-9. http://www.ncbi.nlm.nih.gov/pubmed/18657011?dopt=AbstractPlus
311. Abraham NS, Hlatky MA, Antman EM et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. JACC. 2010; 56: Published online Nov 8, 2010.
317. Furlanetto TW, Faulhaber GA. Hypomagnesemia and Proton Pump Inhibitors: Below the Tip of the Iceberg. Arch Intern Med. 2011; :. http://www.ncbi.nlm.nih.gov/pubmed/21555654?dopt=AbstractPlus
318. Fernández-Fernández FJ, Sesma P, Caínzos-Romero T et al. Intermittent use of pantoprazole and famotidine in severe hypomagnesaemia due to omeprazole. Neth J Med. 2010; 68:329-30. http://www.ncbi.nlm.nih.gov/pubmed/21071783?dopt=AbstractPlus
319. Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM. 2010; 103:387-95. http://www.ncbi.nlm.nih.gov/pubmed/20378675?dopt=AbstractPlus
320. Shabajee N, Lamb EJ, Sturgess I et al. Omeprazole and refractory hypomagnesaemia. BMJ. 2008; 337:a425. http://www.ncbi.nlm.nih.gov/pubmed/18617497?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2483862&blobtype=pdf
321. . In brief: PPI’s and hypomagnesemia. Med Lett Drugs Ther. 2011; 53:25.
322. Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf). 2008; 69:338-41. http://www.ncbi.nlm.nih.gov/pubmed/18221401?dopt=AbstractPlus
323. Broeren MA, Geerdink EA, Vader HL et al. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med. 2009; 151:755-6. http://www.ncbi.nlm.nih.gov/pubmed/19920278?dopt=AbstractPlus
324. Metz DC, Sostek MB, Ruszniewski P et al. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol. 2007; 102:2648-54. http://www.ncbi.nlm.nih.gov/pubmed/17764495?dopt=AbstractPlus
325. Kuipers MT, Thang HD, Arntzenius AB. Hypomagnesaemia due to use of proton pump inhibitors--a review. Neth J Med. 2009; 67:169-72. http://www.ncbi.nlm.nih.gov/pubmed/19581665?dopt=AbstractPlus
326. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006; 355:1834-6. http://www.ncbi.nlm.nih.gov/pubmed/17065651?dopt=AbstractPlus
327. US Food and Drug Administration. FDA drug safety communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs). Rockville, MD; 2011 March 2. From FDA website. http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm
328. US Food and Drug Administration. Proton pump inhibitor drugs (PPIs): Drug safety communication- Low magnesium levels can be associated with long-term use. Rockville, MD; 2011 March 2. From FDA website. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm245275.htm
329. Hoorn EJ, van der Hoek J, de Man RA et al. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis. 2010; 56:112-6. http://www.ncbi.nlm.nih.gov/pubmed/20189276?dopt=AbstractPlus
330. Regolisti G, Cabassi A, Parenti E et al. Severe hypomagnesemia during long-term treatment with a proton pump inhibitor. Am J Kidney Dis. 2010; 56:168-74. http://www.ncbi.nlm.nih.gov/pubmed/20493607?dopt=AbstractPlus
331. GlaxoSmithKline. Lanoxin (digoxin) tablets prescribing information. Research Triangle Park, NC; 2009 Aug.
334. Horn JR, Hansten PD. Methotrexate and proton pump inhibitors. Pharm Times. 2012; 78(4). Published online 2012 Apr 9. http://www.pharmacytimes.com/publications/issue/2012/April2012/Methotrexate-and-Proton-Pump-Inhibitors
335. Food and Drug Administration. Drug safety communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). Rockville, MD; 2012 Feb 8. From FDA website. Accessed 2012 May 3l. http://www.fda.gov/Drugs/DrugSafety/ucm290510.htm
336. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010; 31:431-55. http://www.ncbi.nlm.nih.gov/pubmed/20307191?dopt=AbstractPlus
337. Shah S, Lewis A, Leopold D et al. Gastric acid suppression does not promote clostridial diarrhoea in the elderly. QJM. 2000; 93:175-81. http://www.ncbi.nlm.nih.gov/pubmed/10751237?dopt=AbstractPlus
338. Leonard AD, Ho KM, Flexman J. Proton pump inhibitors and diarrhoea related to Clostridium difficile infection in hospitalised patients: a case-control study. Intern Med J. 2012; 42:591-4. http://www.ncbi.nlm.nih.gov/pubmed/22616966?dopt=AbstractPlus
339. Kwok CS, Arthur AK, Anibueze CI et al. Risk of Clostridium difficile Infection With Acid Suppressing Drugs and Antibiotics: Meta-Analysis. Am J Gastroenterol. 2012; 107:1011-9. http://www.ncbi.nlm.nih.gov/pubmed/22525304?dopt=AbstractPlus
340. Dial S, Delaney JA, Barkun AN et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005; 294:2989-95. http://www.ncbi.nlm.nih.gov/pubmed/16414946?dopt=AbstractPlus
341. Nerandzic MM, Pultz MJ, Donskey CJ. Examination of potential mechanisms to explain the association between proton pump inhibitors and Clostridium difficile infection. Antimicrob Agents Chemother. 2009; 53:4133-7. http://www.ncbi.nlm.nih.gov/pubmed/19667292?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2764230&blobtype=pdf
343. Tibotec Therapeutics. Edurant (rilpivirine) tablets prescribing information. Raritan, NJ; 2011 May.
344. Abbott Laboratories. Kaletra (lopinavir/ritonavir) oral tablets and solution prescribing information. North Chicago, IL; 2012 May.
345. ViiV Healthcare. Lexiva (fosamprenavir calcium) tablets and oral suspension prescribing information. Research Triangle Park, NC; 2012 Apr.
346. Genentech USA. Invirase (saquinavir mesylate) capsules and tablets prescribing information. South San Francisco, CA; 2012 Feb.
348. Merck Sharp & Dohme. Isentress (raltegravir) film-coated tablets and chewable tablets prescribing information. Whitehouse Station, NJ; 2012 Apr.
350. Frelinger AL, Lee RD, Mulford DJ et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012; 59:1304-11. http://www.ncbi.nlm.nih.gov/pubmed/22464259?dopt=AbstractPlus
351. Angiolillo DJ, Gibson CM, Cheng S et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011; 89:65-74. http://www.ncbi.nlm.nih.gov/pubmed/20844485?dopt=AbstractPlus
Medical Disclaimer
Other brands: Aciphex, Aciphex Sprinkle
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.
Source: Drugs.com Rabeprazole Sodium (www.drugs.com/rabeprazole.html).
Commonly reported side effects of rabeprazole include: atrophic gastritis. See below for a comprehensive list of adverse effects.
Applies to rabeprazole: oral capsule delayed release, oral tablet enteric coated
Along with its needed effects, rabeprazole may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking rabeprazole:
Less common
Rare
Incidence not known
Some side effects of rabeprazole may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
Less common
Applies to rabeprazole: oral delayed release capsule, oral delayed release tablet, oral tablet extended release
The most commonly reported side effects are headache, diarrhea, and abdominal pain.
Very common (10% or more): Diarrhea (up to 21%), abdominal pain (up to 16%), vomiting (up to 14%)
Common (1% to 10%): Benign fundic gland polyps, constipation, flatulence, nausea
Uncommon (0.1% to 1%): Dry mouth, dyspepsia, eructation
Rare (0.01% to 0.1%): Gastritis, stomatitis
Frequency not reported: Microscopic colitis
Postmarketing reports: Clostridium difficile-associated diarrhea
Common (1% to 10%): Asthenia, non-specific pain, pain
Uncommon (0.1% to 1%): Chills, pyrexia/fever
Postmarketing reports: Sudden death
Common (1% to 10%): Cough, pharyngitis, rhinitis
Uncommon (0.1% to 1%): Bronchitis, sinusitis
Postmarketing reports: Dyspnea, interstitial pneumonia
Common (1% to 10%): Dizziness, headache, taste disturbance/perversion
Uncommon (0.1% to 1%): Somnolence
Rare (0.01% to 0.1%): Hepatic encephalopathy
Postmarketing reports: Coma, vertigo
Hepatic encephalopathy occurred in patients with underlying cirrhosis.
Common (1% to 10%): Flu-like syndrome/ influenza-like illness, infection
Common (1% to 10%): Back pain, myalgia
Uncommon (0.1% to 1%): Arthralgia, fracture of hip/wrist/spine, leg cramps
Postmarketing reports: Bone fractures, rhabdomyolysis
Common (1% to 10%): Rash
Uncommon (0.1% to 1%): Erythema
Rare (0.01% to 0.1%): Bullous reactions, pruritus, sweating
Very rare (less than 0.01%): Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN)
Frequency not reported: Facial swelling, subacute cutaneous lupus erythematosus
Postmarketing reports: fatal TEN, other drug eruptions, severe dermatological reactions, systemic lupus erythematosus, urticarial skin eruptions
Erythema and bullous reactions usually resolved after discontinuation.
Common (1% to 10%): Insomnia
Uncommon (0.1% to 1%): Nervousness
Rare (0.01% to 0.1%): Depression
Frequency not reported: Confusion
Postmarketing reports: Delirium, disorientation
Common (1% to 10%): Chest pain
Uncommon (0.1% to 1%): Peripheral edema
Postmarketing reports: Hypotension
Uncommon (0.1% to 1%): Increased hepatic enzymes
Rare (0.01% to 0.1%): Hepatitis, jaundice, serious hepatic dysfunction
Increased hepatic enzymes occurred in patients with underlying cirrhosis.
Uncommon (0.1% to 1%): Urinary tract infection
Rare (0.01% to 0.1%): Leukocytosis, leukopenia, neutropenia, thrombocytopenia
Postmarketing reports: Agranulocytosis, bicytopenia, blood dyscrasias, hemolytic anemia, increase in prothrombin time/INR, pancytopenia
Increased prothrombin time/INR occurred in patients taking warfarin concomitantly.
Rare (0.01% to 0.1%): Anorexia, weight gain
Frequency not reported: Cyanocobalamin (Vitamin B-12) deficiency, hypomagnesemia, hyponatremia
Postmarketing reports: Hyperammonemia
Rare (0.01% to 0.1%): Interstitial nephritis
Rare (0.01% to 0.1%): Visual disturbance
Postmarketing reports: Blurred vision
Frequency not reported: Gynecomastia
Postmarketing reports: Thyroid stimulating hormone (TSH) elevations
Hypersensitivity reactions included facial swelling, hypotension, dyspnea, erythema, and bullous reactions; these reactions typically resolved after discontinuation.
Rare (0.01% to 0.1%): Hypersensitivity
Postmarketing reports: Acute systemic allergic reactions, anaphylaxis/anaphylactic reactions, angioedema, potential allergic reactions
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.
Source: Drugs.com Rabeprazole Sodium (www.drugs.com/rabeprazole.html).
May 12, 2020
May 12, 2020
May 12, 2020
May 12, 2020
May 12, 2020
May 11, 2020
